Drugs / Neoadjuvant cadonilimab combined with perioperative SOX
Neoadjuvant cadonilimab combined with perioperative SOX
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06949033 Background | May 2025 → Dec 2028 expected | gastroesophageal cancer | Zuoyi Jiao | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoadjuvant cadonilimab combined with perioperative SOX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06949033 ↗ |
| Route | Oral | “S1: 40-60 mg/m², po, day 1-14 of every 3 weeks” NCT06949033 ↗ |